产品
编 号：F359135
分子式：C41H63NO14S
分子量：826
分子式：C41H63NO14S
分子量：826
产品类型
规格
价格
是否有货
500μg
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 441045-17-6
产品详情
生物活性：
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
体内研究：
Eribulin mesylate (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice.Eribulin mesylate (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase.Animal Model:C3H/HeN mice (4-week-old) are injected LM8 cells
Dosage:1 mg/kg
Administration:I.v. once a week for 2 weeks
Result:Suppressed primary tumor growth and induced apoptosis in tumor cells.Reduced lung metastasis.
体外研究：
Eribulin mesylate (1-100 nM; 72 h) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively.Eribulin mesylate (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells.Eribulin mesylate (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells.Eribulin mesylate (1-50 nM; 12 h) does not induce senescence in LM8 cells.Eribulin mesylate (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells.
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
体内研究：
Eribulin mesylate (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice.Eribulin mesylate (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase.Animal Model:C3H/HeN mice (4-week-old) are injected LM8 cells
Dosage:1 mg/kg
Administration:I.v. once a week for 2 weeks
Result:Suppressed primary tumor growth and induced apoptosis in tumor cells.Reduced lung metastasis.
体外研究：
Eribulin mesylate (1-100 nM; 72 h) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively.Eribulin mesylate (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells.Eribulin mesylate (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells.Eribulin mesylate (1-50 nM; 12 h) does not induce senescence in LM8 cells.Eribulin mesylate (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备